Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [8]
- Comments [0]
- Validations
- Western blot [1]
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB801-100 - Provider product page
- Provider
- R&D Systems
- Product name
- Human CXCL13/BLC/BCA-1 Antibody
- Antibody type
- Monoclonal
- Description
- Protein A or G purified from hybridoma culture supernatant. Detects human CXCL13/BLC/BCA-1 in ELISAs and Western blots. In ELISAs, no cross-reactivity with recombinant human (rh) CXCL1, rhCXCL2, rhCXCL3, rhCXCL8/IL-8, rhCXCL10, rhCXCL9, rhCXCL12/SDF-1 alpha , or rhCXCL12/SDF-1 beta is observed. In Western blots, no cross-reactivity with recombinant mouse CXCL13/BLC/BCA-1 is observed.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Antigen sequence
O43927- Isotype
- IgG
- Antibody clone number
- 53610
- Vial size
- 100 ug
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Methotrexate-associated lymphoproliferative disorders of T-cell phenotype: clinicopathological analysis of 28 cases.
Epidemiology and secular trends of malignant lymphoma in Japan: Analysis of 9426 cases according to the World Health Organization classification.
Diminished CXCR5 expression in peripheral blood of patients with Sjögren's syndrome may relate to both genotype and salivary gland homing.
A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade.
Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis.
Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients.
Hyaluronan-based polymer scaffold modulates the expression of inflammatory and degradative factors in mesenchymal stem cells: Involvement of Cd44 and Cd54.
IL1beta and TNFalpha differently modulate CXCL13 chemokine in stromal cells and osteoblasts isolated from osteoarthritis patients: evidence of changes associated to cell maturation.
Satou A, Tabata T, Miyoshi H, Kohno K, Suzuki Y, Yamashita D, Shimada K, Kawasaki T, Sato Y, Yoshino T, Ohshima K, Takahara T, Tsuzuki T, Nakamura S
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019 Jul;32(8):1135-1146
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019 Jul;32(8):1135-1146
Epidemiology and secular trends of malignant lymphoma in Japan: Analysis of 9426 cases according to the World Health Organization classification.
Muto R, Miyoshi H, Sato K, Furuta T, Muta H, Kawamoto K, Yanagida E, Yamada K, Ohshima K
Cancer medicine 2018 Nov;7(11):5843-5858
Cancer medicine 2018 Nov;7(11):5843-5858
Diminished CXCR5 expression in peripheral blood of patients with Sjögren's syndrome may relate to both genotype and salivary gland homing.
Aqrawi LA, Ivanchenko M, Björk A, Ramírez Sepúlveda JI, Imgenberg-Kreuz J, Kvarnström M, Haselmayer P, Jensen JL, Nordmark G, Chemin K, Skarstein K, Wahren-Herlenius M
Clinical and experimental immunology 2018 Jun;192(3):259-270
Clinical and experimental immunology 2018 Jun;192(3):259-270
A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade.
Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, Kiialainen A, Hanhart J, Schill C, Hess C, Savic Prince S, Wiese M, Lardinois D, Ho PC, Klein C, Karanikas V, Mertz KD, Schumacher TN, Zippelius A
Nature medicine 2018 Jul;24(7):994-1004
Nature medicine 2018 Jul;24(7):994-1004
Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis.
Edwards KR, Goyal J, Plavina T, Czerkowicz J, Goelz S, Ranger A, Cadavid D, Browning JL
PloS one 2013;8(11):e81007
PloS one 2013;8(11):e81007
Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients.
Panse J, Friedrichs K, Marx A, Hildebrandt Y, Luetkens T, Barrels K, Horn C, Stahl T, Cao Y, Milde-Langosch K, Niendorf A, Kröger N, Wenzel S, Leuwer R, Bokemeyer C, Hegewisch-Becker S, Atanackovic D
British journal of cancer 2008 Sep 16;99(6):930-8
British journal of cancer 2008 Sep 16;99(6):930-8
Hyaluronan-based polymer scaffold modulates the expression of inflammatory and degradative factors in mesenchymal stem cells: Involvement of Cd44 and Cd54.
Lisignoli G, Cristino S, Piacentini A, Cavallo C, Caplan AI, Facchini A
Journal of cellular physiology 2006 May;207(2):364-73
Journal of cellular physiology 2006 May;207(2):364-73
IL1beta and TNFalpha differently modulate CXCL13 chemokine in stromal cells and osteoblasts isolated from osteoarthritis patients: evidence of changes associated to cell maturation.
Lisignoli G, Cristino S, Toneguzzi S, Grassi F, Piacentini A, Cavallo C, Facchini A, Mariani E
Experimental gerontology 2004 Apr;39(4):659-65
Experimental gerontology 2004 Apr;39(4):659-65
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Detection of Recombinant Human CXCL13/BLC/BCA-1 by Western Blot. Western blot shows 100 ng of Recombinant Human CXCL13/BLC/BCA-1 (Catalog # 801-CX) and Recombinant Mouse CXCL13/BLC/BCA-1 (Catalog # 470-BC). PVDF Membrane was probed with 1 µg/mL of Mouse Anti-Human CXCL13/BLC/BCA-1 Monoclonal Antibody (Catalog # MAB801) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for CXCL13/BLC/BCA-1 at approximately 12 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 3.
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Chemotaxis Induced by CXCL13/BLC/BCA-1 and Neutralization by Human CXCL13/BLC/BCA-1 Antibody. Recombinant Human CXCL13/BLC/BCA-1 (Catalog # 801-CX) chemoattracts the BaF3 mouse pro-B cell line transfected with human CXCR5 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Mouse Anti-Human CXCL13/BLC/BCA-1 (0.05 µg/mL) is neutralized (green line) by increasing concentrations of Human CXCL13/BLC/BCA-1 Monoclonal Antibody (Catalog # MAB801). The ND50 is typically 0.3-0.9 µg/mL.
